Asenapine and Fluvoxamine interaction
Asenapine and Fluvoxamine: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Asenapine (SAPHRIS) label · effective 2025-01-31
Marginal increase of asenapine exposure was observed when SAPHRIS is used with fluvoxamine at 25 mg administered twice daily [ see Clinical Pharmacology ( 12.3 )] .
However, the tested fluvoxamine dose was suboptimal.
Full therapeutic dose of fluvoxamine is expected to cause a greater increase in asenapine exposure.
Strong CYP1A2 Inhibitors (e.g., Fluvoxamine) SAPHRIS is metabolized by CYP1A2.
From the Fluvoxamine (fluvoxamine maleate) label · effective 2026-04-23
CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) .
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.